PNC Financial Services Group’s MoonLake Immunotherapeutics MLTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $205K | Sell |
4,340
-4,860
| -53% | -$229K | ﹤0.01% | 2187 |
|
|
2025
Q1 | $359K | Buy |
9,200
+700
| +8% | +$27.3K | ﹤0.01% | 1764 |
|
|
2024
Q4 | $460K | Buy |
8,500
+320
| +4% | +$17.3K | ﹤0.01% | 1600 |
|
|
2024
Q3 | $412K | Buy |
8,180
+44
| +0.5% | +$2.22K | ﹤0.01% | 1675 |
|
|
2024
Q2 | $358K | Buy |
8,136
+1,322
| +19% | +$58.1K | ﹤0.01% | 1730 |
|
|
2024
Q1 | $342K | Buy |
6,814
+667
| +11% | +$33.5K | ﹤0.01% | 1792 |
|
|
2023
Q4 | $371K | Buy |
6,147
+2,067
| +51% | +$125K | ﹤0.01% | 1699 |
|
|
2023
Q3 | $233K | Sell |
4,080
-247
| -6% | -$14.1K | ﹤0.01% | 2009 |
|
|
2023
Q2 | $221K | Buy |
+4,327
| New | +$221K | ﹤0.01% | 2127 |
|